Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses
2024

Multipoint Pacing Improves Heart Failure Treatment

Sample size: 593 publication 10 minutes Evidence: high

Author Information

Author(s): Calò Leonardo, De Ruvo Ermenegildo, Kolb Christof, Janmohamed Amir, Marques Pedro, Defaye Pascal, Marquie Christelle, Piot Olivier, Grammatico Andrea, Lee Kwangdeok, Lin Wenjiao, Burri Haran, Sperzel Johannes, Thibault Bernard, Rinaldi Christopher, Leclercq Christophe

Primary Institution: Policlinico Casilino, Rome, Italy

Hypothesis

Does multipoint pacing (MPP) provide better outcomes than standard biventricular (BIV) pacing in heart failure patients who do not respond to standard CRT?

Conclusion

Multipoint pacing is associated with lower heart failure hospitalizations and a higher probability of reverse left ventricular remodeling compared to standard biventricular pacing.

Supporting Evidence

  • Patients receiving multipoint pacing had a higher rate of LVESV relative reduction ≥15% compared to those receiving standard BIV pacing.
  • HF hospitalizations were significantly lower in the multipoint pacing group.
  • Multivariate analysis confirmed that MPP was associated with a higher probability of being a CRT responder.

Takeaway

This study found that using multipoint pacing can help patients with heart failure feel better and stay out of the hospital more than traditional pacing methods.

Methodology

The study analyzed data from 593 patients who were randomized to receive either multipoint pacing or standard biventricular pacing after being identified as non-responders to CRT.

Potential Biases

Potential conflicts of interest were noted among some authors due to funding from Abbott.

Limitations

The findings are based on a retrospective analysis of a randomized controlled trial, which may limit the generalizability of the results.

Participant Demographics

{"age":"67 ± 10 years","gender":{"female":"22.6%","male":"77.4%"},"NYHA_class":{"II":"50.8%","III":"46.9%","IV":"2.2%"},"ischemic_cardiomyopathy":"54.0%"}

Statistical Information

P-Value

0.0103

Confidence Interval

1.02–2.34

Statistical Significance

p = 0.0103

Digital Object Identifier (DOI)

10.1093/europace/euae259

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication